Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders [clinicaltrials:NCT00122629]
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders [clinicaltrials:NCT00122629]
Bio2RDF identifier
NCT00122629
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00122629
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
Triple antiviral therap ...... ne or a placebo for 48 weeks.
brief title [clinicaltrials_vocabulary:brief-title]
Triple Therapy With Peg-Interf ...... s C Virus (HCV) Non Responders
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2003-05-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Triple antiviral therap ...... erapy at weeks 12, 24 and 48.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-07-20T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Amantadine
Hepatitis C, Chronic
peginterferon alfa-2b
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2005-07-28T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00122629
official title [clinicaltrials_vocabulary:official-title]
Triple Therapy With Peg-Interf ...... Non Responders ANRSHC03 BITRI
org study id [clinicaltrials_vocabulary:org-study-id]
ANRSHC03 BITRI
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2000-10-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2005-07-01T00:00:00Z
identifier
clinicaltrials:NCT00122629
title
Triple Therapy With Peg-Interf ...... s C Virus (HCV) Non Responders
@en
type
label
Triple Therapy With Peg-Interf ...... s [clinicaltrials:NCT00122629]
@en